ChemoTech obtain approval of the third and last patent application in India

Scandinavian ChemoTech AB today announces that it has been granted its third and last patent application by The Patent Office, Government of India. The approved patent application pertains to the utilization of TSE for pain alleviation.

The Patent Office, Government of India has approved the third and final patent application. This approval allows for the utilization of TSE by delivering dynamic electrical pulses with pinpoint accuracy to specific body parts of mammals, enabling effective pain management, in amongst others deep seated tumours. The protection extends to 2038.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: [email protected]

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.